Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
biotech
boston blog main
clinical trials
eli lilly
fda
2
×
indiana blog main
indiana top stories
lasmiditan
life sciences
migraine research foundation
2
×
national blog main
raleigh-durham blog main
2
×
raleigh-durham top stories
teva pharmaceutical
triptans
2
×
alder biopharmaceutical
allergan
alprazolam
american academy of neurology
atogepant
biohaven
bob azelby
boston top stories
botox
boulder/denver blog main
boulder/denver top stories
brian abrahams
calcitonin gene-related peptide
cgrp inhibitors
chronic migraine
colucid pharmaceuticals
detroit blog main
detroit top stories
drug enforcement administration
drugs
eptinezumab
erenumab
fremanezumab
galcanezumab
What
approval
decades
drug
fda
migraine
new
2
×
won
acute
addresses
arguments
big
causes
class
commercialized
companies
competitors
condition
drugs
eli
friday
giant
giving
lasmiditan
lilly
lilly’s
make
medication
meeting
neuro
oks
oral
pharmaceutical
potential
second
therapies
year
Language
unset
Current search:
won���t
×
new
×
" migraine research foundation "
×
" raleigh-durham blog main "
×
fda
×
triptans
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments